利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.034 秒)

    MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT
    3.
    发明申请
    MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT 审中-公开
    乳腺癌诊断标记，测试方法和测试包

    公开(公告)号：US20130012412A1

    公开(公告)日：2013-01-10

    申请号：US13618415

    申请日：2012-09-14

    申请人： Masahiko KURODA ,  Masami TANAKA ,  Kosuke OIKAWA ,  Takayuki MIZUTANI ,  Masakatsu TAKANASHI

    发明人： Masahiko KURODA ,  Masami TANAKA ,  Kosuke OIKAWA ,  Takayuki MIZUTANI ,  Masakatsu TAKANASHI

    IPC分类号： C40B30/04

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.

    摘要翻译： 本发明的一个实施方案提供了可以检测在早期阶段（临床阶段0）不能通过触诊或乳房X线照相检查或乳腺癌检测到的乳腺癌发作的标志物，测试方法和测试试剂盒，其为 简单，可靠性高。 与本发明实施方案的乳腺癌相关的标志物的特征在于是在血清或血浆中发现的微RNA。 更具体地，标记物在乳腺癌发作后或在乳腺早期（临床阶段0期间或之后）期间或之后存在于血清或血浆中存在的至少一种微RNA，其显着降低水平 与乳腺癌发病前或乳腺癌早期（临床阶段0之前）癌症相比较。

    CANCER CELL IDENTIFICATION MARKER AND CANCER CELL PROLIFERATION INHIBITOR
    4.
    发明申请
    CANCER CELL IDENTIFICATION MARKER AND CANCER CELL PROLIFERATION INHIBITOR 有权
    癌细胞鉴定标记和癌细胞增殖抑制剂

    公开(公告)号：US20130172400A1

    公开(公告)日：2013-07-04

    申请号：US13613626

    申请日：2012-09-13

    申请人： Masahiko KURODA ,  Masakatsu Takanashi ,  Kosuke Oikawa

    发明人： Masahiko KURODA ,  Masakatsu Takanashi ,  Kosuke Oikawa

    IPC分类号： C12N15/113

    CPC分类号： C12N15/113 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/57496

    摘要： Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1γ (HP1γ), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1γ gene, such as siRNAs to human HP1γ.

    摘要翻译： 公开了可用于检测各种人类癌细胞并且其表达与细胞的恶性改变密切相关的鉴定标记物，以及基于通过抑制识别标志物表达抑制癌细胞增殖的人类癌症治疗用组合物 。 该标记物是人异染色质蛋白质1gamma（HP1gamma），并且用于癌症治疗的组合物包含一种或多种抑制人HP1gamma基因（例如人HP1gamma的siRNA）表达的试剂。

    METHOD FOR EVALUATING CANCER
    7.
    发明申请
    METHOD FOR EVALUATING CANCER 审中-公开
    癌症评估方法

    公开(公告)号：US20140178874A1

    公开(公告)日：2014-06-26

    申请号：US14032651

    申请日：2013-09-20

    申请人： Masahiko KURODA ,  Akira SAITO ,  Maki SANO

    发明人： Masahiko KURODA ,  Akira SAITO ,  Maki SANO

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.

    摘要翻译： 提供了一种使用新型癌症标志物评价受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。 使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评价中的新型癌症标志物。 检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。 根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。 作为检测癌症标记物的方法，优选使用例如相对于被固定化的样品的标记探针进行原位杂交法。